

**Organized by:**

Hellenic Society of Geriatric Oncology  
Oncology Center of Biomedical Education & Research  
Turkish Society of Medical Oncology


**Under the auspices of:**

National and Kapodistrian University,  
Medical School, Athens, Greece  
Istanbul University, Medical School,  
Istanbul, Turkey

# 5<sup>th</sup> LUNG CANCER Network

«From the Bench to the Bedside»

January | 18 - 20 | 2018 - Hilton Athens | Greece



Accreditation from:  
Panhellenic Medical Association

## SCIENTIFIC PROGRAM

## Invitation Letter

The recent, increasing amount of knowledge regarding lung cancer, especially in the field of basic science, holds promise for personalized treatment of these patients that would provide more effective and less toxic therapeutic approaches, improving the prognosis of the patients with thoracic malignancies. On the other hand, the immense bulk and the rapid recycling of the new information makes difficult its understanding, evaluation and interpretation by the clinicians. Therefore, the «translation» of our recently acquired knowledge from the lab bench to the bedside is neither smooth nor is it without obstructions, due to the existing «gaps» in our understanding and the often contradictory «signals» from clinical trials.

The success of our four previous meetings has prompted us to organize the **5<sup>th</sup> Lung Cancer Network «From the Bench to the Bedside»**. Our aim is to narrow the distance between the bench lab and the patient's bed, between the clinical trials outcome and the routine practice, by bringing together basic scientists, clinical researchers and lung cancer specialists. Our multidisciplinary, international faculty will present the latest clinical data and provide treating physicians with practical information regarding the clinical significance of the histological, molecular and genetic profile of the tumor and how the implementation of targeted agents in the therapeutic algorithm changes the clinical practice of lung cancer patients.

Finally, we anticipate that our meeting, with the presence of our distinguished faculty, would provide the opportunity and motivation for discussions regarding the emerging therapies and set the pavement for the future research and strategies towards the personalized treatment of lung cancer patients.

We cordially welcome you all in Athens in January 18-20 2018 for a stimulating, innovative and educational meeting.

## Learning Objectives

At the end of our educational meeting, the participant will be able to:

- Recognize the clinical significance of molecular genotyping of lung cancer patients
- Understand the molecular pathways that hold promise for therapeutic intervention in lung cancer patients
- Update of Immunotherapy strategies for lung cancer
- Discuss the optimal methodology of evaluation of response in the era of translational research
- Recognize the importance of a multidisciplinary approach to the care of lung cancer patients

## Topics

- Neuroendocrine lung cancer update
- Tumor heterogeneity
- Prognostic and predictive tumor Markers
- Molecular signaling of LC
- NSCLC driver oncogenes
- Immunotherapy
- Evaluation of response
- Master protocols in lung cancer
- Agents related toxicity management
- Newer generation TKIs inhibitors

## Target Audience

The meeting is designed for medical, radiation and surgical oncologists, pathologists, chest physicians, scientists, residents-in-training, fellows and other health care professionals interested in the basic and clinical research as well as in the management of thoracic cancers.

## The Chairs of the Meeting



**Kostas Syrigos, MD, PhD, FCCP**

Professor & Head of Medicine and Medical Oncology  
Athens University School of Medicine, Greece  
Vis. Professor, Yale School of Medicine, USA



**David Rimm, MD, PhD**

Professor, Director of Translational Pathology  
Yale University School of Medicine, USA



**Yesim Eralp, MD**

Professor of Medical Oncology  
and Internal Medicine  
Istanbul University Institute of Oncology  
Istanbul, Turkey



**Dimitrios Kardamakis**

Professor, Radiation Oncology  
Dean of School of Health Sciences  
University of Patras Medical School  
Patra, Greece

## Organizing & Scientific Committees

### Organizing Committee

- Chairmen:** David Rimm  
Kostas Syrigos
- Members:** Andriani Charpidou  
Yeşim Eralp  
Giannis Gkiozos  
Dimitris Kardamakis  
Ilias Kotteas  
Sofia Tsagouli

### Scientific Committee

- Chairmen:** Yeşim Eralp  
Dimitris Kardamakis
- Vice Chairmen:** Giannis Gkiozos  
Kostas Syrigos
- Members:**
- |                        |                          |                           |
|------------------------|--------------------------|---------------------------|
| Panagiotis Bechrakis   | Paraskevi Katsaounou     | Kyriaki Tavernaraki       |
| Richard Booton         | Nikolaos Kentepozidis    | Levon Toufektzian         |
| Paraskevi Boura        | Keith Kerr               | Rodoula Tringidou         |
| Elisabeth Brambilla    | George Kontopyrgias      | Sofia Tsagouli            |
| Andriani Charpidou     | Françoise Mornex         | Sotirios Tsiboukis        |
| Achilles Chatziioannou | Vali Papadimitrakopoulou | Georgios Tsoukalas        |
| Lucio Crino            | Aggeliki Papaspiliou     | Serdar Turhal             |
| Elif Dağlı             | Nir Peled                | Konstantinos Vachlas      |
| Ahmet Demirkazik       | Maria Piperis            | Ioannis Vamvakaris        |
| Rafal Dziadziuszko     | Robert Pirker            | Johan Vansteenkiste       |
| Wilfried Eberhardt     | Aikaterini Politi        | Antonios Vassias          |
| Enriqueta Felip        | Pieter Postmus           | Dimitrios Vassos          |
| Angeliki Florou        | Konstantinos Potaris     | Fulden Yumuk              |
| Vasileios Georgoulas   | Noemi Reguart            | Heather Wakelee           |
| Scott Gettinger        | David Rimm               | Konstantinos Zarogoulidis |
| Maya Gottfried         | Christian Rolfo          | Lambros Zellos            |
| Fred Hirsch            | Angelica Saetta          | Christoph Zielinski       |
| Kosmas Iliadis         | Vasileios Skouras        |                           |
| Charalampos Kalofonos  | Grigorios Stratakis      |                           |

# Scientific Program

THURSDAY

**January 18<sup>th</sup>**

2 0 1 8

08:45-09:00 Registrations - Welcome

## 09:00-11:00 **Prevention & tobacco control**

Chairs: **Panagiotis Bechrakis, Andriani Charpidou**

09:00-09:30	Epidemiology of lung cancer.	<b>Vasilios Skouras</b>
09:30-10:00	Successful tobacco control approaches.	<b>Paraskevi Katsaounou</b>
10:00-10:30	Smoking cessation into CT screening.	<b>Paraskevi Boura</b>
10:30-11:00	New challenges: waterpipes & e-cigarettes.	<b>Angeliki Florou</b>

## 11:00-11:30 **Coffee break**

## 11:30-13:30 **Screening and early detection**

Chairs: **Grigoris Stratakos, Achilles Chatziioannou**

11:30-12:00	Perspectives in lung cancer imaging.	<b>Kyriaki Tavernarakis</b>
12:00-12:30	Most recent clinical trials.	<b>Sofia Tsagouli</b>
12:30-13:00	Endoscopy for early detection.	<b>George Kontopyrgias</b>
13:00-13:30	Other modalities for early detection.	<b>Dimitrios Vassos</b>

## 13:30-13:45 **Break**

## 13:45-14:30 **Biology, pathology and molecular testing**

Chairs: **Nikolaos Kentepozidis, Rodoula Tringidou**

13:45-14:00	Immunohistochemical assesment of biomarkers for immunotherapy.	<b>Aikaterini Politi</b>
14:00-14:15	Next generation sequencing.	<b>Angelica Saetta</b>
14:15-14:30	The clinical impact of 2015 WHO classification.	<b>Ioannis Vamvakaris</b>

## 14:30-16:30 **Light lunch**

## 16:30-18:00 **NSCLC - treatment of localized disease**

Chairs: **Kosmas Iliadis, Vassilios Georgoulas**

16:30-16:50	Sublobar resections for early stage NSCLC.	<b>Lambros Zellos</b>
16:50-17:10	Evaluation of mediastinum.	<b>Konstantinos Vachlas</b>
17:10-17:30	Minimal invasive modalities of treatment.	<b>Konstantinos Potaris</b>
17:30-17:50	Stereotactic ablative body radiotherapy.	<b>Maria Piperis</b>
17:50-18:00	Discussion	

## 18:00-18:30 **Break**



THURSDAY **January 18<sup>th</sup>** 2 0 1 8

- 18:30-19:30 Mesothelioma management**  
Chairs: **Georgios Tsoukalas, Antonios Vassias**
- 18:30-19:00 Novel therapies and biomarkers in MPM. **Aggeliki Papaspiliou**  
19:00-19:30 Immunotherapy in mesothelioma. **Sotirios Tsiaboukis**
- 
- 19:30-20:30 Lung cancer registry**  
Chairs: **K. Syrigos, G. Gkiozos**
- Eleni Kokkotou**  
**Ilias Maniadakis**  
Commentator: **G. Gkiozos**

FRIDAY **January 19<sup>th</sup>** 2 0 1 8

- 09:00-11:00 Thoracic Oncology Highlights 2017 (I)**  
Chairs: **Fulden Yumuk, Giannis Gkiozos**
- 09:00-09:30 Screening for lung cancer - update and ways for implementation. **Nir Peled**  
09:30-10:00 Thoracic surgery updates. **Levon Toufektzian**  
10:00-10:30 Advances in radiation oncology. **Françoise Mornex**  
10:30-11:00 Medical oncology updates. **Vali Papadimitrakopoulou**
- 11:00-11:30 Coffee break**
- 11:30-13:30 Thoracic Oncology Highlights 2017 (II)**  
Chairs: **Konstantinos Zarogoulidis, Charalambos Kalofonos**
- 11:30-12:00 Current treatment approaches for SCLC. **Maya Gottfried**  
12:00-12:30 Global tobacco control updates. **Elif Dağlı**  
12:30-13:00 Symptom management in lung cancer. **Richard Booton**  
13:00-13:30 Thoracic malignancies beyond NSCLC and MPM. **Fulden Yumuk**
- 13:30-16:00 Light lunch**
- 16:00-17:00 Satellite symposium**

FRIDAY

**January 19<sup>th</sup>**

2 0 1 8

**17:00-18:30****Lung cancer immunotherapy. State-of-the-art**Chairs: **Nir Pelled, David Rimm**

17:00-17:20

The BLUEPRINT and related studies:  
a comparative review.**Fred Hirsch**

17:20-17:40

Predictive biomarkers for immuno-oncology.

**David Rimm**

17:40-18:00

Immunotherapy duration and treatment  
discontinuation.**Enriqueta Felip**

18:00-18:20

Management of immune checkpoint inhibitors  
toxicity.**Yeşim Eralp**

18:20-18:30

Discussion

**18:30-19:30****Satellite symposium****19:30****Welcome cocktail**

Saturday

**January 20<sup>th</sup>**

2 0 1 8

**09:00-11:00****Lung cancer: is tissue still the issue?**Chairs: **Heather Wakelee, Fred Hirsch**

09:00-09:20

Appropriate and optimized handling of biopsy or  
cytology specimens.**David Rimm**

09:20-09:40

How to approach mixed histologies and metastatic  
histology.**Kith Kerr**

09:40-10:00

How to incorporate liquid biopsies into clinical  
practice.**Fulden Yumuk**

10:00-10:20

What to do when tissue and plasma are discordant.

**Nir Peled**

10:20-10:40

Liquid biopsy biomarkers in IO.

**Christian Rolfo****11:00-11:30****Coffee break****11:30-13:00****Driver oncogenes (+ve) NSCLC patients: a changing landscape**Chairs: **David Rimm, Pieter Postmus**

11:30-11:50

The evolving treatment algorithm in  
EGFR-mutated NSCLC.**Wilfried Eberhardt**

11:50-12:10

Treatment options for patients with ALK+ NSCLC.

**Yeşim Eralp**

12:10-12:30

Resistance to ALK and ROS1 inhibitors.

**Christoph Zielinski**

12:30-12:50

Emerging targeted therapies in NSCLC.

**Vali Papadimitrakopoulou**

12:50-13:00

Discussion

Saturday

January 20<sup>th</sup>

2 0 1 8

**13:00-13:30 Break**

**13:30-14:30 Management of non-oncogene driven NSCLC patients**

Chairs: **Scott Gettinger, Christoph Zielinski**

13:30-13:50 The role of antiangiogenic therapies in NSCLC. **Ahmet Demirkazik**

13:50-14:10 Anti-EGFR therapies in unselected NSCLC patients. **Serdar Turhal**

14:10-14:30 Optimal therapeutic algorithm in squamous NSCLC. **Noemi Reguart**

**14:30-15:00 Satellite lecture**

**15:00-16:00 Satellite symposium**

**16:00-17:00 Thoracic tumors beyond NSCLC**

Chairs: **Johan Vansteenkiste, Lucio Crino**

16:00-16:20 Emerging therapies in SCLC. **Maya Gottfried**

16:20-16:40 Neuroendocrine tumors: pathology and genetic update. **Elisabeth Brambilla**

16:40-17:00 Emerging therapies for mesothelioma. **Pieter Postmus**

**17:00-17:15 Break**

**17:15-18:45 Lung cancer immunotherapy: the perspectives (I)**

Chairs: **Wilfried Eberhardt, Scott Gettinger**

17:15-17:35 How to evaluate the efficacy of IO? **Heather Wakelee**

17:35-17:55 How to sequence immunotherapy between 1<sup>st</sup> and 2<sup>nd</sup> line? **Scott Gettinger**

17:55-18:15 Rationale for IO/IO combinations. **Johan Vansteenkiste**

18:15-18:35 Rationale for immuno-radiotherapy combinations. **Rafal Dziadziuszko**

18:35-18:45 Discussion

**18:45-20:15 Lung cancer immunotherapy: the perspectives (II)**

Chairs: **Yeşim Eralt, Dimitris Kardamakis**

18:45-19:05 Acquired resistance to PD-1 axis inhibitors. **Scott Gettinger**

19:05-19:25 Immunotherapy in elderly. **Fulden Yumuk**

19:25-19:45 Value-based judgment in advanced NSCLC. **Robert Pirker**

19:45-20:05 Rationale for combination of chemotherapy with IO. **Lucio Crino**

20:05-20:15 Discussion

**20:15 Conclusions**

**Dimitris Kardamakis**



## Scientific Information

### Meeting room - audiovisual - technical support

The meeting will take place at the «Hesperides» Hall and the meeting secretariat will operate at the «Hesperides» Foyer during the sessions. The meeting room will be equipped with data video projectors, laser pointers etc for power point presentations. Technical support center will be available outside the «Hesperides» Hall. Technical staff will assist with the presentations. All speakers are kindly requested to submit their presentation at least one hour prior to their scheduled presentation.



### CME Accreditation

The content of the meeting will be submitted for CME accreditation. Accreditation will be received from the Panhellenic Medical Association.

### Name badges

All registered participants will receive name badges, which they are kindly requested to wear at all times. Each badge will have a barcode for monitoring the hours of attendance.

### Certificate of Attendance

All registered participants who have attended at least 60% of the total scientific program will receive a certificate of attendance from the secretariat desk after the closing ceremony.

## General information

### Organized by

Hellenic Society of Geriatric Oncology  
Oncology Center of Biomedical Education & Research  
Turkish Society of Medical Oncology

### Under the auspices of:

National and Kapodistrian University, Medical School, Athens, Greece  
Istanbul University, Medical School, Istanbul, Turkey

### Meeting website

[www.lungcancernetwork.eu](http://www.lungcancernetwork.eu)

### Meeting dates

January 18-20, 2018

### Meeting venue

Hilton Athens Hotel  
46 Vassilissis Sofias Avenue  
115 28 Athens, Greece  
Tel.: 00 30 210 72 81 000

### Registration cost

Type of registration	Cost
Doctors	200€
Residents	100€
Nurses	free
Medical students	free

Registration cost includes:

- Admission to all sessions & exhibition area
- Meeting material
- Certificate of attendance

### Meeting's Secretariat



#### E.T.S. Events & Travel Solutions S.A.

El. Venizelou 154, 171 22 N. Smyrni - Athens, Greece

Tel.: +30 210 98 80 032, Fax: +30 210 98 81 303

E-mail: [ets@otenet.gr](mailto:ets@otenet.gr), [ets@events.gr](mailto:ets@events.gr), Website: [www.events.gr](http://www.events.gr)